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Abstract
Coronavirus disease of 2019 (COVID-19) is associated with hypercoagulopathy, but haemorrhage, including spontaneous
intracerebral parenchymal haemorrhage and diffuse petechial cerebral haemorrhage, has also been reported. We present two
cases of nonaneurysmal subarachnoid haemorrhage (SAH) in patients with severe COVID-19. Careful review of neuroimaging
for haemorrhagic complications of COVID-19 should be undertaken, particularly for those patients receiving enhanced prophy-
laxis for venous thromboembolism. Although likely to be a marker of severe disease, non-aneurysmal SAH can be associated
with favourable outcome.
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Introduction
Although a predisposition to thrombosis in COVID-19
is well-recognised [1, 2], reports of haemorrhage affect-
ing multiple organ systems, including the CNS are
emerging [3, 4]. The pathophysiology is not yet fully
understood and may be multifactorial including
microthrombosis with secondary haemorrhage, dysregu-
lated coagulation, e.g. disseminated intravascular coagu-
lation and immune thrombocytopenic purpura [5], and
vascular hyperpermeability in the context of COVID-
19 cytokine storm [1], endotheliitis [6] and vasculitis
[7].
We report 2 cases of non-aneurysmal SAH in severe
COVID-19 and hypothesise that this occurred as a com-
plication of thromboembolic disease in the context of
enhanced prophylaxis for thromboembolic disease.
These cases add to the clinical spectrum of neurological
complications associated with COVID-19 and highlight
the importance of careful review of neuroimaging in
patients with severe COVID-19.
Patient A
A 74-year-old gentleman with confirmed COVID-19 and
type 1 respiratory failure was admitted to the intensive
care unit for mechanical ventilatory support. Maximum
blood pressure was 130/55 mmHg. He received
enoxaparin 40 mg bd subcutaneously as enhanced pro-
phylaxis for venous thromboembolism [8]. Markers of
disease severity included fibrinogen > 6 g/L, D-dimer as-
s ay va l u e 55 μg /m l , f e r r i t i n 1808 μg /L and
neutrophil:lymphocyte ratio 13. [9] At day 11, a CT head
scan performed for reduced conscious level following se-
dation hold demonstrated multifocal, small volume, con-
vexity SAH (Figs. 1 and 2). CSF analysis confirmed SAH
(red blood cells 7614/mm3, white blood cells < 5/mm3,
protein 1.1 g/L, negative for viral studies including
SAR-CoV-2). The platelet count transiently fell 3 days
prior to CT head scan (36 × 109/L), but clotting studies
were otherwise normal. A weakly positive lupus antico-
agulant was detected together with anti-cardiolipin IgG
antibodies (55 GPLU). Beta-2-glycoprotein 1 IgG and
IgM were normal (< 10 U/ml). Paroxysmal atrial fibrilla-
tion was noted. Electroencephalogram was consistent
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with encephalopathy. An MRI brain scan demonstrated
SAH with small multifocal infarcts and normal magnetic
resonance angiography appearances (Fig. 1); SAH
colocalised with areas of infarction but was also more
widely distributed. On transthoracic echocardiography, a
pedunculated mobile mass consistent with thrombus was
seen within the left atrium attached to the inferior limbic
band region. Blood cultures were sterile. Anticoagulation
was held for 2 weeks, and interval neuroimaging exclud-
ed additional intracranial haemorrhage or new infarction
following which he was fully anticoagulated. The mobile
structure within the left atrium was reduced in size on
follow-up transthoracic echocardiography. With contin-
ued supportive therapies, his level of consciousness
improved, and he has been discharged for ongoing
rehabilitation.
Patient B
A 53-year-old gentleman with confirmed COVID-19 and
type 1 respiratory failure required mechanical ventilatory
support. Markers of disease severity included ferritin
2107 μg/L, fibrinogen > 6 g/L, D-dimer assay value
18.5 μg/ml and neutrophil:lymphocyte ratio 32.
Maximum blood pressu re was 152 /60 mmHg.
Enoxaparin was given 40 mg bd subcutaneously [8].
Raised clozapine level (4.6 mg/L, normal range 0.35–
0.6 mg/L) was noted. CT head scan following seizure
activity on sedation withdrawal demonstrated multifocal,
curvilinear foci of sulcal high density consistent with
SAH which was not present on historical imaging (Fig.
1). Coagulation studies were normal throughout.
Electroencephalogram was consistent with encephalopa-
thy. CSF analysis and MRI brain scan (complicated by
motion artefact), performed > 7 days later, were normal.
Blood tests were satisfactory with the exception of
oligoclonal pattern on serum immunofixation. With con-
tinued supportive therapies, his level of consciousness
improved. He has subsequently been discharged from
the intensive care unit for continued rehabilitation.
Discussion
We report 2 cases of nonaneurysmal SAH which have oc-
curred in patients with severe COVID-19. We have attributed
this to thromboembolism in the context of enhanced venous
thromboembolism prophylaxis; alternative causes for non-
aneurysmal SAH including reversible cerebral vasoconstric-
tion syndrome, posterior reversible encephalopathy syndrome
or cerebral amyloid angiopathy were considered unlikely
based on the investigation results.
These cases highlight that, although prophylaxis and treat-
ment of thrombosis associated with COVID-19 are undoubt-
edly important, clinicians should be alert to the possibility of
haemorrhagic complications, particularly those associated
with thromboembolic disease. Careful review of neuroimag-
ing for subtle changes consistent with nonaneurysmal sub-
arachnoid haemorrhage is required. Although likely to be a
marker of severe disease due to COVID-19, SAH can be as-
sociated with a favourable outcome.
Fig. 1 Non-aneurysmal SAH co-existent with COVID-19 (MRI). In pa-
tient A (a–f), brain MRI results demonstrated multifocal convexity high
signal change consistent with acute subarachnoid haemorrhage and small
infarcts including in the left precentral gyrus (a and b axial T1, c and d
coronal fluid-attenuated inversion recovery, e axial diffusion, f axial sus-
ceptibility weighted imaging)
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